Smart drug delivers chemo directly to cancer cells in new trial
NCT ID NCT07439094
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called CKD-703 in people with advanced solid tumors or non-small cell lung cancer that has a specific protein (c-Met). The drug is designed to attach to cancer cells and release chemotherapy directly inside them, aiming to kill the cancer while reducing harm to healthy cells. The trial will enroll 140 adults and first check safety and dosing, then measure how well the drug shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CKD-703 (an antibody-drug conjugate that targets c-Met and delivers a chemotherapy drug directly to cancer cells)
What this could lead to
If successful, this could provide a new targeted treatment option for people with certain advanced cancers, especially non-small cell lung cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2a) with a small number of participants, so the drug may not prove effective or may cause unexpected side effects. It is also only for people with specific genetic markers (c-Met), limiting who can benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gabrail Cancer Center
RECRUITINGOhio City, Ohio, 44718, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••